ClinicalTrials.gg
Active, not recruitingNCT05347134Updated May 8, 2026

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

A Phase 3 interventional study of SKB264 in Triple Negative Breast Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms — 9 open to participants now, 11 under way, 5 of them phase 3. sacituzumab tirumotecan · Triple Negative Breast Neoplasms.

Planned enrollment
5th of 12
254 · median 152
Started
2022
with 1 other
Phase 3
5 of 12
3 open now
Primary completion
2023-11
later than 0 of 10 live
Registered
1st of 12
by date
Lead sponsor
3 of 12
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Among the 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms, this one is the 5th largest by planned enrollment, is one of 2 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 1st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 444 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

9 of the 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About sacituzumab tirumotecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing sacituzumab tirumotecan in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care

Read the detailed description

The 2021 CSCO guidelines recommend treatment for patients with advanced TNBC as follows: Taxoides are generally preferred for patients who have failed anthracycline therapy in the past; For patients with anthracycline and taxane treatment failure, there is no standard therapy. Previously unused chemotherapy alone or in combination can be considered. However, the toxicity of combination chemotherapy is high and the survival benefit is limited, therefore, in consideration of the quality of life of advanced patients, single-agent chemotherapy is recommended as a priority.

03

Conditions studied

  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will not be included unless they meet all of the following criteria:

  1. Males or females age 18 to 75 years old (inclusive) at the time of signing the form;
  2. and/or cytologically confirmed TNBC based on pathology reports on recent specimens or other pathological samples (central laboratory confirmation is not required), including:

    1. Definition of human epidermal growth factor receptor 2 () negative: immunohistochemistry (IHC) of 0 or 1+; if HER is 2+ by IHC, negative HER2 expression must be confirmed by fluorescence in situ hybridization (FISH).
    2. Estrogen and progesterone receptor negative means that less than 1% of the cells express hormone receptors as indicated by IHC;
  3. Patients with unresectable locally advanced or triple-negative breast cancer who have received at least two lines of standard of care regimens, including:

    1. Any treatment received by the patients regardless of triple-negative state can be included as one of the standard of care regimens;
    2. For patients whose treatment regimens have been changed due to intolerability to toxicity, the intolerable regimens can be included as one of the prior standard of care regimens;
    3. For and/or adjuvant chemotherapy, if relapse or disease progression to unresectable locally advanced or metastatic disease occurs during treatment or within 12 months after discontinuation of treatment (at least 2 cycles have been completed), it will be considered as one of the standard of care regimens. And the patients must also have received one therapy and have progressed on this therapy during the stage of unresectable locally advanced or metastatic disease;
    4. For patients with documented germline BRCA1/BRCA2 mutations, if they have been treated with an approved PARP inhibitor, then the PARP inhibitor can be considered as one of the 2 prior standard of care regimens required;
    5. Patients must have progressed on or were intolerable to the treatment during or after the last treatment prior to enrollment;
  4. All patients must have been previously treated with taxanes; and those who have been treated with taxanes for at least 1 cycle and show or intolerability during or at the end of the cycle can be included, regardless of the disease stage during this treatment;
  5. Patients must have at least one per v1.1 criteria; those with only skin or bone lesions cannot be included;
  6. Subjects with a (ECOG) performance status of 0 to 1 with an expected survival of ≥ 12 weeks;
  7. Subjects must provide tumor tissues or tissue specimens;
  8. Subjects must have adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin, or colony stimulating factor therapy has been received within 2 weeks prior to the screening), which is defined as follows:

    1. Hematology: (NEUT) ≥ 1.5 × 109 /L; (PLT) ≥ 100 × 109 /L; ≥ 9 g/dL;
    2. Liver function: (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × (ULN); total (TBIL) ≤ 1.5 × ULN; for patients with liver metastases, ALT and AST must be ≤ 5 × ULN, TBIL ≤ 2 × ULN; for patients with liver or bone metastases, ALP must be ≤ 5 × ULN;
    3. Albumin ≥ 3 g/dL;
    4. Renal function: (Ccr) ≥ 60 ml/min (see Annex for Cockcroft-Gault formula);
    5. Coagulation function: (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5 × ULN;
  9. Subjects must have recovered from all toxicities (except alopecia) due to prior treatments to ≤ grade 1 based on the assessment per 5.0 criteria;
  10. Subjects voluntarily participate in the study, sign the informed consent form, and will be able to comply with the protocol-specified visits and relevant procedures.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded:

  1. Patients with a history of central nervous system (CNS) or current ;
  2. Patients with other , except cured basal or squamous cell skin cancer or in situ cancer of cervix; and patients with other malignancies must have a tumor-free period of at least 5 years;
  3. Patients with Gilbert's disease;
  4. Patients who have received prior TROP2-targeted therapy;
  5. Patients who have received within 30 days prior to the first dose;
  6. Patients who required the treatment of strong inhibitors or inducers of cytochrome P450 3A4 enzyme () within 2 weeks prior to the first dose and during the study treatment (strong inhibitors or inducers of CYP3A4 are not allowed in this study, and representative drugs of strong CYP3A4 inhibitors or inducers are listed in the Annex). Patients who received continued high dose of systemic within 2 weeks prior to the first dose (low-dose corticosteroids, such as ≤ 10 mg daily prednisone or equivalent, are allowed if the dose is stable for 4 weeks);
  7. Patients who have received any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biological therapy or other drugs within 4 weeks prior to the first dose of study treatment or within 5 half-lives of the drug used in the previous period (whichever is shorter), or received treatment with traditional Chinese medicine preparations for approved anti-tumor indications 2 weeks prior to the first dose of study treatment, or received major surgeries 4 weeks prior to the first dose of study treatment;
  8. With concomitant infections requiring systemic antibiotic therapy within 1 week prior to the first dose of study treatment;
  9. Presence of any serious and/or uncontrolled comorbidities that prevent the patient from participating in the study, such as:

    1. Impaired cardiac function, including any of the following: (not necessarily all of the following):

      aa) interval (QTcF) between ventricular depolarization to repolarization > 480 ms at baseline; ab) (LVEF) \< 50% as indicated by echocardiography (ECHO) ;

    2. Other heart diseases, including any of the following known medical history:

      ba) Angina pectoris; bb) Congestive cardiac failure; bc) Myocardial infarction;

    3. Patients with (noninfectious) interstitial lung disease (ILD) or history of pneumonia requiring steroid therapy; patients with serious pulmonary function impairment due to lung disease;
    4. Patients with current or previous active chronic inflammatory bowel disease or intestinal obstruction or gastrointestinal (GI) perforation;
    5. Uncontrolled hypertension (systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg), with a history of unstable hypertension, or with a history of poor compliance with antihypertensive treatment;
    6. Uncontrolled diabetes (fasting glucose ≥ 10 mmol/L and/or (HbA1c) ≥ 8%);
  10. Active (hepatitis B surface antigen positive, and HBV-DNA above 500 IU/ml or 1x , whichever is higher) or (hepatitis C antibody positive, and HCV-RNA above 1x ULN); with known history of positive (HIV) test or known acquired immunodeficiency syndrome (AIDS); positive syphilis antibody test;
  11. History of serious drug allergy, with known allergy to macromolecular protein preparations or any component of the study drug formulation;
  12. Pregnant or lactating women; or patients of (male or female) who cannot use effective medical during the study treatment period and for 6 months after the end of the dosing period (see Annex for specific contraceptive measures);
  13. During the screening process prior to the first dose, the condition deteriorated rapidly, such as severe changes in performance status, unstable pain requiring adjustment of analgesic therapy;
  14. Other circumstances that, in the opinion of the investigator, are not appropriate for participation in this study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
254 participants (estimated)

Study arms

  • Active comparator
    SKB264

    5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle.

    Drug: SKB264

  • Active comparator
    Eribulin or Capecitabine or Gemcitabine or Vinorelbine

    Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21day cycle. Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.

    Drug: SKB264

Interventions

  • DrugSKB264

    SKB264 :5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

    Also known as: Eribulin, Capecitabine, Gemcitabine, Vinorelbine

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) as assessed by an Independent Review Committee (IRC) based on RECIST 1.1

    Time frame: up to 24 months

Secondary outcomes

  1. Progression-free survival(PFS)

    Progression-free survival (PFS) assessed by the investigators according to RECIST V 1.1

    Time frame: up to 24 months

  2. Objective Response Rate (ORR)

    The percentage of patients with CR and PR assessed by the Independent Review Committee and investigators according to RECIST v 1.1

    Time frame: up to 24 months

  3. Disease Control Rate (DCR)

    The proportion of patients who have achieved CR,PR and SD assessed by the Independent Review Committee and investigators according to RECIST v 1.1

    Time frame: up to 24 months

  4. Duration of Response (DoR)

    From the date that response criteria are first met to the first occurrence of PD as determined by the Independent Review Committee and investigators according to RECIST v1.1 or death from any cause, whichever occurs first

    Time frame: up to 24 months

  5. Overall Survival (OS)

    OS, defined as the time from randomization to death or lose of follow, whichever occurs first

    Time frame: up to 24 months

07

Study locations

2 sites
08

References and documents

Publications

  • Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, Li M, Yan X, Wang S, Sun T, Teng Y, Tang X, Tong Z, Sun Z, Ge J, Jin X, Diao Y, Liu G, Xu B. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025 Jun;31(6):1969-1975. doi: 10.1038/s41591-025-03630-w. Epub 2025 Apr 11. PubMed 40217078 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Nov 2023, 17 months.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2022
First posted
Apr 26, 2022
StartActual
Jun 10, 2022
Primary completionActual
Nov 30, 2023
CompletionEst.
Jun 30, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05347134
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Jun 10, 2022
Primary completion
Nov 30, 2023
Completion
Jun 30, 2027 (estimated)
Last update
May 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion